Clinical Characteristics and Chemosensitivity in Germline TP53 Pathogenic Variant Cases Identified by Cancer Genomic Testing
Cancer Genomics - Proteomics · 2025
DOI: 10.21873/cgp.20506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, 2025. Verfasst von Yosuke Saito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Yamagata City Hospital Saiseikan, Yamagata, Japan. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Germ-Line Mutation, Neoplasms, Li-Fraumeni Syndrome. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Yamagata City Hospital Saiseikan, Yamagata, Japan.
- Department of Genetic Counseling, Yamagata University Faculty of Medicine, Yamagata, Japan.
- Department of Respiratory Medicine, Okitama General Hospital, Kawanishi, Japan.
- Yamagata Hereditary Tumor Research Center, Yamagata University School of Medicine, Yamagata, Japan.
- Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan.
- Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Japan.
Zitieren
APA
Saito, Y., Hoshi, Y., Sato, M., Seino, M., Watanabe, N., Kawai, M., & Suzuki, S. (2025). Clinical Characteristics and Chemosensitivity in Germline TP53 Pathogenic Variant Cases Identified by Cancer Genomic Testing. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20506
Vancouver
Saito Y, Hoshi Y, Sato M, Seino M, Watanabe N, Kawai M, et al. Clinical Characteristics and Chemosensitivity in Germline TP53 Pathogenic Variant Cases Identified by Cancer Genomic Testing. Cancer Genomics - Proteomics. 2025. doi:10.21873/cgp.20506
BibTeX
@article{Saito2025,
author = {Saito, Yosuke and Hoshi, Yuki and Sato, Masamichi and Seino, Manabu and Watanabe, Norikazu and Kawai, Masaaki and Suzuki, Shuhei},
title = {Clinical Characteristics and Chemosensitivity in Germline TP53 Pathogenic Variant Cases Identified by Cancer Genomic Testing},
journal = {Cancer Genomics - Proteomics},
year = {2025},
doi = {10.21873/cgp.20506}
}
EUVIMED